Core Laboratories (NYSE:CLB) shares reached a new 52-week high and low during trading on Thursday . The stock traded as low as $125.13 and last traded at $123.76, with a volume of 281729 shares changing hands. The stock had previously closed at $120.51.
Several research analysts have commented on the stock. TheStreet raised shares of Core Laboratories from a “c” rating to a “b-” rating in a report on Thursday, February 1st. Zacks Investment Research downgraded shares of Core Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, April 18th. ValuEngine raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, April 11th. Cowen set a $98.00 price objective on shares of Core Laboratories and gave the company a “hold” rating in a report on Friday, April 13th. Finally, Credit Suisse Group assumed coverage on shares of Core Laboratories in a report on Thursday, March 15th. They set an “outperform” rating and a $107.94 price objective for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company. Core Laboratories currently has an average rating of “Hold” and a consensus target price of $112.99.
The company has a current ratio of 1.98, a quick ratio of 1.66 and a debt-to-equity ratio of 1.53. The firm has a market cap of $5,220.22, a P/E ratio of 62.27 and a beta of 1.41.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 22nd. Investors of record on Friday, April 27th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date is Thursday, April 26th. Core Laboratories’s payout ratio is 110.00%.
Several large investors have recently made changes to their positions in CLB. DF Dent & Co. Inc. bought a new position in shares of Core Laboratories in the 4th quarter valued at about $77,449,000. TimesSquare Capital Management LLC bought a new position in shares of Core Laboratories in the 4th quarter valued at about $32,005,000. WCM Investment Management CA lifted its holdings in shares of Core Laboratories by 5.5% in the 4th quarter. WCM Investment Management CA now owns 4,793,731 shares of the oil and gas company’s stock valued at $525,153,000 after acquiring an additional 250,830 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Core Laboratories in the 4th quarter valued at about $12,836,000. Finally, Millennium Management LLC bought a new position in shares of Core Laboratories in the 4th quarter valued at about $11,887,000.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.